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Objective: There remains no general consensus in the neurosurgical oncology literature
regarding the role of extent of glioma resection in improving patient outcome. Although the
value of resection in establishing a diagnosis and alleviating mass effect is clear, there is less
certainty in ascertaining the influence of extent of resection (EOR). Here, we review the
recent literature to synthesize a comprehensive review of the value of extent of resection
for gliomas in the modern neurosurgical era. Methods: We reviewed every major peer-
reviewed clinical publication since 1990 on the role of EOR in glioma outcome. Results:
Thirty-two high-grade glioma articles and 11 low-grade glioma articles were examined in
terms of quality of evidence, expected EOR, and survival benefit. Conclusion: Despite
limitations in the quality of data, mounting evidence suggests that more extensive surgi-
cal resection is associated with longer life expectancy for both low- and high-grade newly
diagnosed gliomas.
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INTRODUCTION
Gliomas are the most common primary malignant brain tumor
in adults, yet outcomes from this aggressive neoplasm remain dis-
mal. In the modern era, the multimodal management of these
tumors begins with microsurgical resection whenever possible.
Advances in intraoperative technique, including neuronavigation,
intraoperative magnetic resonance imaging, intraoperative ultra-
sound, stimulation mapping techniques, and fluorescence-guided
surgery, have all been developed to maximize tumor resection and
minimize surgical morbidity for both low- and high-grade gliomas
(Barker et al., 1996; Stummer et al., 2006; Sanai and Berger, 2009,
2010; Kubben et al., 2011).
The elucidation of prognostic factors and treatment options for
glioma remains a challenge. Patient age and tumor histology have
been identified as reliable predictors of patient prognosis among
tumor- and treatment-related variables, and patient functional
status can also be predictive of outcome. The use of biomark-
ers such as IDH1/2 and MGMT-methylation status is increasingly
common, although the exact role for such markers in routine clin-
ical management remains undefined. The importance of surgical
debulking in obtaining a tissue diagnosis and to alleviate symp-
toms from mass effect is clear, but a lack of Level I evidence
limits certainty in assessing the influence of extent of resection
(EOR). Despite significant advances over the last two decades in
brain tumor imaging and intraoperative technology, the actual
impact of glioma resection in extending tumor-free progression,
patient quality of life, and patient overall survival remains unclear.
With this in mind, we have examined every major clinical pub-
lication from 1990 to 2012 that reports on the role of EOR in
glioma outcome. Our objective is to synthesize a comprehen-
sive assessment of EOR in the modern neurosurgical era, as well
as to critically examine the quality of evidence in the published
literature. Lastly,we aim to identify the magnitude of improvement
in patient survival, if any, that can be achieved with the degree
of EOR.
METHODS
A literature search of the PubMed database from January 1990
to June 2012 was conducted using the following key words:
“high-grade glioma,”“low-grade glioma,”“astrocytoma,”“anaplas-
tic astrocytoma,” “oligodendroglioma,” “oligoastrocytoma,” and
“glioblastoma (GBM).”
English-language series including adult patients with hemi-
spheric gliomas were identified. Before analyzing the studies in
detail, we conducted additional screening. Small series (<75
patients), or those with incomplete methodological data (such
as specification of how EOR was assessed), were eliminated. Also
excluded were those studies where EOR was recorded only as a
volume of residual tumor, or those studies that only compared
resection to biopsy. We excluded series that had both adult and
pediatric patients if the adult patients had not been analyzed sepa-
rately. Studies including pilocytic and gemistocytic astrocytomas,
where data regarding patients with these tumors were not sepa-
rated from other low-grade gliomas, were excluded. Based upon
these criteria, we found 32 studies examining EOR for high-grade
gliomas and 11 studies examining EOR for low-grade gliomas
(Tables 1–6).
For these remaining studies, we considered the statistical analy-
sis that affected interpretation of data. This assessment included
the identification of potential methodological flaws and informa-
tion that was omitted from the publication. The methodological
parameters we evaluated included choice of statistical tests and
adjustment for confounding variables. The specific information
that we searched for consisted of discussion of possible sources
of bias in selection of cases, number of events (deaths), length
of follow-up for patients without events, i.e., survivors, hazard
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Table 1 |Volumetric EOR studies in high-grade glioma.
Study Tumor
grade(s)
Patients Extent of
resection (N )
Overall survival
Mean survival
(months)
Univariate
analysis p value
Multivariate
analysis p value
Keles et al. (1999) IV 107 <25% (25) 8.0 NA <0.0005
25–49% (21) 14.2
50–74% (18) 15.7
75–99% (20) 22.1
100% (23) 23.3
Pope et al. (2005) IV 110 <20% 27.4 NS NS
20–89% 11.1
90–99% 17.1
100% 22.1
Lacroix et al. (2001) IV 416 <98% 8.8 <0.0001 <0.0001
≥98% 13.0
Keles et al. (2006) III 102 0–100% 41.0 NS NS
Sanai et al. (2011) IV 500 >77% 12.5 <0.0001 0.004
>79% 12.8
>89% 13.8
100% 16
ratios, and confidence intervals. We sought to identify potential
confounders underlying predictor variables. For example, it could
be possible that all patients in whom a subtotal resection (STR)
was achieved underwent adjuvant chemoradiation and that none
of those in whom a total resection was achieved underwent such
therapy. We also looked for a specific statement of how the mul-
tivariate analysis, if any, was conducted. Because none of these
studies were prospective randomized trials, we looked for how
many patients were in each of the analyzed subsets, to determine
if studies were adequately powered to see statistically significant
differences.
Preoperative and postoperative tumor volumes, from which
the EOR is calculated, have been considered as possible prognostic
factors. We therefore identified publications to find studies that
included evaluations of preoperative and residual tumor volumes
on outcome. High-grade gliomas were in all series defined by the
enhancing region on a T1-weighted MRI. For low-grade gliomas,
tumor volume and EOR were calculated upon T2-weighted MR
imaging. Tumor progression was defined by the radiographic pro-
gression of these MRI features. Studies using volumetric tumor
analysis were evaluated separately, as this method can dramatically
affect EOR calculations (Sanai and Berger, 2008, 2009).
RESULTS
HIGH-GRADE GLIOMA STUDIES TO DATE – AN OVERVIEW
Thirty-two studies were identified between 1990 and 2012 exam-
ining EOR and high-grade glioma patient outcomes (Shibamoto
et al., 1990; Vecht et al., 1990; Hollerhage et al., 1991; Phillips et al.,
1991; Sandberg-Wollheim et al., 1991; Curran et al., 1992; Dun-
can et al., 1992; Prados et al., 1992; Dinapoli et al., 1993; Huber
et al., 1993; Simpson et al., 1993; Jeremic et al., 1994; Warnke
et al., 1994; Nitta and Sato, 1995; Barker et al., 1996; Kowalczuk
et al., 1997; Keles et al., 1999, 2006; Buckner et al., 2001; Lacroix
et al., 2001; Levin et al., 2002; Puduvalli et al., 2003; Tortosa et al.,
2003; Lamborn et al., 2004; Brown et al., 2005; Pope et al., 2005;
Stark et al., 2005; Ushio et al., 2005; Nomiya et al., 2007). Most,
but not all, studies used standard WHO grading criteria; other
grading systems were utilized in a minority of reports (Dinapoli
et al., 1993; Levin et al., 2002; Stark et al., 2005). Five studies used
volumetric analysis to determine EOR; the other 27 studies used
a combination of 2D postoperative imaging and surgeon judg-
ment to create categories such as gross total resection (GTR), STR,
partial resection (PR), etc.
HIGH-GRADE GLIOMA VOLUMETRIC STUDIES
Among the five volumetric studies, three (N = 1,023, range 107–
500 patients) demonstrated a significant survival benefit for
increasing EOR (Table 1; Keles et al., 1999; Lacroix et al., 2001;
Sanai et al., 2011). These three positive studies examined the value
of EOR in GBM patients only. GTR (EOR= 100%) was associ-
ated with a 2- to 8-month increased survival benefit compared
to STRs (EOR= 50–98%), depending on series. Two volumetric
studies (N = 110 and 102, respectively) showed no patient ben-
efit with increasing EOR, although one study did trend toward
increased patient survival with increased EOR despite statistical
non-significance (Pope et al., 2005; Keles et al., 2006).
HIGH-GRADE GLIOMA NON-VOLUMETRIC STUDIES
Seventeen non-volumetric EOR studies (N = 4,992, range 86–949
patients) demonstrated a survival benefit associated with increased
EOR using univariate or multivariate analyses (Table 2; Shibamoto
et al., 1990; Vecht et al., 1990; Curran et al., 1992; Dinapoli et al.,
1993; Simpson et al., 1993; Jeremic et al., 1994; Nitta and Sato,
1995; Barker et al., 1996; Buckner et al., 2001; Lamborn et al.,
2004; Brown et al., 2005; Stark et al., 2005; Ushio et al., 2005;
Nomiya et al., 2007; Stummer et al., 2008; McGirt et al., 2009a;
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Table 2 | Positive, non-volumetric studies of EOR in high-grade glioma.
Study Tumor
grade(s)
Patients Extent of resection (N ) Overall survival
Mean survival
(months)
Univariate
analysis p value
Multivariate
analysis p value
Vecht et al. (1990) III and IV 243 GTR (15) NA NA 0.001
“Large” (15)
“Small” (57)
“Decompression” (139)
Biopsy (17)
Shibamoto et al. (1990) IV 135 GTR+STR (50) 15 <0.05 NA
PR+Biopsy (85) 11
Simpson et al. (1993) IV 645 GTR (123) 11.3 <0.001 <0.0001
Partial (413) 10.4
Biopsy (109) 6.6
Curran et al. (1992) III 103 GTR (14) 49.3 0.0023 NS
PR (58) 49.3
Biopsy (31) 18.3
Dinapoli et al. (1993) III and IV 346 GTR+STR (246) NA 0.0375 0.0046
Biopsy (100)
Jeremic et al. (1994) IV 86 GTR+STR (61) 14 0.0000 0.00030
Biopsy (25) 7.3
Nitta and Sato (1995) III and IV 101 GTR (26) 20 <0.01 NA
STR (36) 12
PR (39) 11
Barker et al. (1996) IV 222 GTR (28) NA <0.001 0.04
STR (165)
Biopsy (13)
Buckner et al. (2001) III and IV 275 GTR (99) NA 0.54 0.0002
STR (169)
Biopsy (92)
Lamborn et al. (2004) IV 832 GTR (101) NA NA <0.001
STR (469)
Biopsy (86)
Brown et al. (2005) III and IV 124 GTR (49) NA NS <0.001
STR (53)
Biopsy (22)
Ushio et al. (2005) IV 105 GTR (35) 20 0.0048 0.018
PR (57) 14.2
Biopsy (13) 8.3
Stark et al. (2005) IV 267 GTR (167) NA 0.014 NA
STR (80)
PR (14)
Nomiya et al. (2007) III 170 GTR+STR (76) 62.6 <0.0001 0.0001
PR+Biopsy (94) 22.9
Stummer et al. (2008) IV 243 GTR (122) 16.7 <0.001 0.0009
STR (121) 11.8
McGirt et al. (2009a) III and IV 949 GTR (330) 13 0.001 0.001
“Near-total” (388) 11
STR (231) 8
Oszvald et al. (2012)* IV 146 GTR (19) 17.7 <0.0001 <0.05
STR (26) 16.1
PR (35) 11.4
Biopsy (66) 4.0
*Significant for patients aged over 65 years only.
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Table 3 | Negative, non-volumetric studies of EOR in high-grade glioma.
Study Tumor
grade(s)
Patients Extent of
resection (N )
Overall survival
Mean survival
(months)
Univariate
analysis p value
Multivariate
analysis p value
Huber et al. (1993) III and IV 163 NA NA NS NS
Hollerhage et al. (1991) IV 118 NA NA NS NS
Prados et al. (1992) III 357 NA NA NA NS
Duncan et al. (1992) III and IV 235 GTR (39) NA NS NS
STR (121)
Biopsy (75)
Sandberg-Wollheim et al. (1991) III and IV 171 GTR (59) 13.5 NS NS
STR (112) 12.8
Phillips et al. (1991) IV 173 GTR (28) NA NS NS
STR (137)
Biopsy (8)
Kowalczuk et al. (1997) III and IV 75 GTR (30) NA NS NS
STR (32)
Biopsy (13)
Levin et al. (2002) III 92 GTR (20) NA NA NS
STR (45)
Biopsy 25
Puduvalli et al. (2003) III 106 GTR (30) NA NS NS
STR (61) 80.4
Biopsy (14) 33.6
Tortosa et al. (2003) III 95 GTR (33) NA NS NS
PR (33)
Biopsy (29)
Oszvald et al. (2012)* IV 215 GTR (41) 16.5 NS NS
STR (43) 15.0
PR (70) 13.3
Biopsy (61) 7.9
*Non-significant for patients aged under 65 years only.
Table 4 |Volumetric EOR studies in low-grade glioma.
Study Patients Extent of
resection (N )
5-Year overall survival
5-Year survival Univariate
analysis p value
Multivariate
analysis p value
van Veelen et al. (1998) 90 >75% (13) 62% 0.002 0.04
<75% (59) 18%
Claus et al. (2005) 156 100% (56) 98.2% 0.05 <0.05
<100% (100) 92.0%
Smith et al. (2008) 216 0–40% (21) NA NA <0.001
41–69% (39) NA
70–89% (55) NA
90–99% (26) 97.0%
100% (75) 98.0%
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Table 5 | Positive low grade non-volumetric studies.
Study Patients Extent of
resection (N )
5-Year overall survival
5-Year survival Univariate
analysis p value
Multivariate
analysis p value
Philippon et al. (1993) 179 GTR (45) 80% 0.0002 <0.01
STR (95) 50%
Biopsy (39) 45%
Rajan et al. (1994) 82 GTR (11) 90% <0.05 NS
STR (30) 52%
PR (22) 50%
Biopsy (19) 42%
Leighton et al. (1997) 167 GTR (85) 82% 0.008 0.006
STR (23) 64%
Nakamura et al. (2000) 88 Radical (43) NA <0.001 <0.001
Non-radical (45)
Shaw et al. (2002) 203 GTR (29) 88 0.0116 0.0349
STR (71) 56
Biopsy (103) 71
Yeh et al. (2005) 93 GTR (13) 92 0.0349 0.016
STR (71) 52
Biopsy (9) 52
McGirt et al. (2009a) 170 GTR (65) 95% 0.043 0.017
NTR (39) 80%
STR (66) 70%
Table 6 | Negative, non-volumetric studies of EOR in low-grade glioma.
Study Patients Extent of
resection (N )
5-Year overall survival
5-Year survival Univariate
analysis p value
Multivariate
analysis p value
Johannesen et al. (2003) 993 GTR (173) NA NS NS
STR (689)
Biopsy (131)
Oszvald et al., 2012). Due to heterogeneity in EOR classifica-
tion schemes, however, a more detailed meta-analysis of these
series is not possible. Similar to the volumetric studies discussed
above, overall survival was (depending on series) 0.9–8.0 months
longer following GTR as compared to following STR. Of the
14 studies that utilized multivariate analysis to control for age,
performance status, and use of adjuvant therapy, only one such
analysis (Curran et al., 1992) subsequently rendered EOR non-
significant. All other studies using multivariate analysis found
greater EOR to independently be associated with improved sur-
vival (Table 2). Of note, four studies found EOR to only be
associated with increased patient survival in multivariate analysis,
but not univariate analysis. Conversely, 11 non-volumetric studies
(N= 1800, range 75–357 patients) demonstrated no overall sur-
vival benefit associated with increased EOR using either univariate
or multivariate analysis (Table 3; Hollerhage et al., 1991; Phillips
et al., 1991; Sandberg-Wollheim et al., 1991; Duncan et al., 1992;
Prados et al., 1992; Huber et al., 1993; Kowalczuk et al., 1997; Levin
et al., 2002; Puduvalli et al., 2003; Tortosa et al., 2003; Oszvald
et al., 2012). Potential confounders such as use of chemotherapy
and radiation therapy varied widely between publications, but did
not differ significantly among patients receiving greater or lesser
EOR in any individual series.
LOW-GRADE GLIOMA STUDIES TO DATE – AN OVERVIEW
Eleven studies between 1990 and 2012 evaluated EOR and patient
overall and/or progression-free survival for low-grade gliomas
(Philippon et al., 1993; Rajan et al., 1994; Leighton et al., 1997;
van Veelen et al., 1998; Nakamura et al., 2000; Shaw et al., 2002;
Johannesen et al., 2003; Claus et al., 2005; Yeh et al., 2005; Smith
et al., 2008; McGirt et al., 2009a). Histologically, the majority of
tumors were low-grade astrocytomas, but oligoastrocytomas and
oligodendrogliomas were included as a minority of tumors in 10
studies. Three studies used volumetric analysis to determine EOR;
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the other eight studies used either two-dimensional postoperative
imaging parameters or surgeon judgment.
LOW-GRADE GLIOMAS – VOLUMETRIC STUDIES
All three studies to date using volumetric analysis to deter-
mine EOR in low-grade glioma patients (N = 462, range 90–216
patients) have demonstrated a benefit to increasing EOR in uni-
variate and/or in multivariate analysis (Table 4; van Veelen et al.,
1998; Claus et al., 2005; Smith et al., 2008). Five-year overall sur-
vival was improved in all studies; median survival and time to
malignant progression was not always reported. However, in the
most recent report by Smith et al. (2008) greater EOR was also
predictive of increased malignant progression-free survival.
LOW-GRADE GLIOMAS – NON-VOLUMETRIC STUDIES
Among the eight non-volumetric studies examining the survival
benefit associated with EOR for low-grade glioma patients, seven
(N = 982, range 82–203 patients) demonstrated a benefit with
increasing EOR (Table 5; Philippon et al., 1993; Rajan et al.,
1994; Leighton et al., 1997; Nakamura et al., 2000; Shaw et al.,
2002; Yeh et al., 2005; McGirt et al., 2009a). Five-year overall
survival was markedly increased in all series, increasing from
50–70% in STRs to 80–95% in GTR. Cytoreduction remained
a significant predictor in the multivariate analyses of six of the
seven positive studies (Table 5). Malignant progression-free sur-
vival was improved in patients undergoing GTR in the one
series that specifically commented upon malignant progression
(McGirt et al., 2009a). One large study (N = 992) found no sig-
nificant difference between gross total and subtotal resections
in 5-year patient survival (Table 6; Johannesen et al., 2003). As
expected, the use of radiation therapy and chemotherapy var-
ied widely between studies. In seven studies, multivariate analy-
sis adjusted for adjuvant radiation therapy, although, in two
reports, 100% of patients received postoperative radiation ther-
apy regardless of EOR. In one study (McGirt et al., 2009a), no
patient received postoperative radiation therapy prior to disease
progression.
DISCUSSION
To date, no Level I evidence exists comparing EOR and glioma
patient outcome. In the modern neurosurgical era, completion
of a randomized, placebo-controlled trial examining high-grade
glioma EOR remains unlikely. The literature from the last two
decades strongly suggests that increasing EOR improves glioma
patient survival. This may be particularly important in the surgi-
cal resection of low-grade gliomas, where every volumetric EOR
study identified and reviewed here has demonstrated survival ben-
efit. Multiple studies have also found a decrease in malignant
progression for these low-grade lesions with greater EOR, sug-
gesting a surgical alteration of tumor biology (Smith et al., 2008;
McGirt et al., 2009a). This favorable change in the natural his-
tory of these lesions from aggressive resection deserves further
investigation.
For high-grade gliomas, there is heterogeneity in the EOR lit-
erature. The strongest evidence for EOR improving outcome in
GBM comes from the randomized trial of 5-ALA published in
2006 by the ALA-Glioma Study Group (Stummer et al., 2006).
Patients undergoing surgery with the use of 5-ALA had improved
rates of GTR as well as increased 6-month PFS compared to tra-
ditional microsurgical resection; however, because patients were
randomized to treatment group (5-ALA vs. none) rather than
resection category (GTR vs. subtotal), and because subsequent
postoperative care was not universal amongst patients with GTR
and STRs, this study is not Level I evidence for EOR alone improv-
ing outcome. Nevertheless, an extensive retrospective analysis of
the study data by the original authors re-stratifying study patients
to GTR or STR groups identified complete resection (GTR) as an
independent variable in overall survival upon multivariate analy-
sis (Stummer et al., 2008). The ALA-Glioma Study Group data
may therefore be considered Level 2b evidence for increasing EOR
improving GBM patient outcome – the highest level of evidence
from any EOR publication to date. Despite these findings, several
retrospective volumetric studies and numerous non-volumetric
studies have shown no benefit to increased EOR in high-grade
glioma patients. Nevertheless, the overwhelming majority (11 of
14) of large high-grade glioma series (>200 patients), do show sur-
vival benefit with greater EOR (Vecht et al., 1990; Duncan et al.,
1992; Prados et al., 1992; Dinapoli et al., 1993; Simpson et al.,
1993; Barker et al., 1996; Buckner et al., 2001; Lacroix et al., 2001;
Lamborn et al., 2004; Stark et al., 2005; Stummer et al., 2008;
McGirt et al., 2009a; Sanai et al., 2011; Oszvald et al., 2012). Thus,
it remains possible that most of these negative small series may
be underpowered to detect a clinically and statistically significant
difference.
Balancing cytoreduction with the risk of neurological mor-
bidity is a common theme in many recent reports. Although no
study has directly compared this relationship, retrospective stud-
ies demonstrate an association between new postoperative deficit
and decreased overall survival or worsened functional outcome
(McGirt et al., 2009b; Gulati et al., 2011). Interestingly, several
large series have demonstrated no difference in new postoperative
neurological deficits between patients undergoing GTR vs. subto-
tal glioma resection (Stummer et al., 2008; McGirt et al., 2009b;
Sanai et al., 2011). However, in an analysis of neurological mor-
bidity provided by the ALA-Glioma Study Group, patients in the
ALA group had more frequent deterioration on the NIH-Stroke
Scale at 48 h (Stummer et al., 2011). Importantly, techniques such
as intraoperative cortical stimulation mapping may help mitigate
the risks of aggressive glioma resection in eloquent territories (De
Witt Hamer et al., 2012).
Many other critical questions remain unanswered. The effect
of EOR for different histological subtypes of tumor must be stud-
ied, as tumor biology unquestionably plays a role in determining
its response to cytoreduction and, perhaps, its ease of obtain-
ing GTR. Similarly, tumor biomarkers known to predict response
to adjuvant therapy or overall survival (such as 1p/19q, IDH1/2,
and MGMT-methylation) should also be incorporated into future
analyses. Also, it is unclear whether the correlation between EOR
and survival holds true for both first-time and recurrent opera-
tions in either low- or high-grade patients. Lastly, the efficacy of
emerging adjuvant therapies, such as bevacizumab, should also be
studied in the context of EOR.
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CONCLUSION
Our review of all studies in the modern neurosurgical era for
both low- and high-grade adult supratentorial gliomas highlights
recent literature that associate more extensive microsurgical resec-
tion with improved life expectancy. In GBM, this level of evidence
reaches Level 2b from retrospective analysis of randomized trial
data; most evidence is Level 3 from retrospective case series. In
addition to providing greater overall survival, more aggressive
resections for low-grade gliomas may also impact the natural his-
tory of the disease, favorably altering its risk profile for malignant
transformation. A prospective, randomized study using modern
intraoperative techniques and standardized perioperative adjuncts
remains the gold-standard in settling the controversy, but such a
trial may never occur. For the time being, retrospective matched
studies, retrospective reviews of randomized trials, or prospective
observational trials remain the most practical solutions.
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